Columbia Healthcare

columbia-china.com

Columbia Healthcare China was founded by Columbia Pacific Management Inc.(CPM). With headquarter is in Seattle, USA, CPM is an international business that develops and operates hospitals, clinics and senior living facilities. CPM has nearly 30 hospitals, clinics, and extended care facilities in Malaysia, India, Vietnam and Indonesia. In Year 2011, Columbia China set up the head office in Shanghai. To meet China's growing demand for international standard medical services, Columbia China will invest in the establishment of a number of comprehensive, specialized hospitals, clinics, pension care and rehabilitation facilities throughout the country.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

SCINEURO PHARMACEUTICALS AND MABYLON AG TO COLLABORATE ON DEVELOPMENT OF NOVEL THERAPEUTICS FOR NEUROLOGICAL DISEASES

SciNeuro Pharmaceuticals | October 26, 2021

news image

SciNeuro Pharmaceuticals a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, and Mabylon AG, a leader in the discovery and characterization of human-derived antibodies against therapeutic targets, today announced the establishment of a multi-program collaboration and license agreement. Under the collaboration, MabSciNeuro and Mabylon will collaborate on multiple targets that encompass serious neurological diseases including TAR DNA bin...

Read More

LANTERN PHARMA’S PROPRIETARY A.I. PLATFORM SURPASSES 450 MILLION DATA POINTS ACCELERATING ONCOLOGY DRUG DEVELOPMENT AND DRUG RESPONSE PREDICTION

Lantern Pharma | June 30, 2020

news image

Lantern Pharma, a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and...

Read More

Pharmacy Market

PAN-TB COLLABORATION ANNOUNCES THE START OF A PHASE 2 CLINICAL TRIAL TO EVALUATE TWO NOVEL TUBERCULOSIS TREATMENT REGIMENS

PRNewswire | August 10, 2023

news image

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the Bill & Melinda Gates Medical Research Institute (Gates MRI). The trial will evaluate whether novel regimens that combine registered products and new chemical entities have the potential to effectively treat drug-sensitive TB (DS-TB) and inform the development of a "pan-TB" regimen capable of treating all forms of active pu...

Read More

Business Insights

ELLIPSES PHARMA AND SUNROCK BIOPHARMA ENTER INTO A LICENSING AGREEMENT FOR A FIRST-IN-CLASS BIFUNCTIONAL HER3:TRAIL FUSION PROTEIN

SunRock Biopharma S.L | May 26, 2022

news image

SunRock Biopharma S.L. a biopharmaceutical company that is developing a portfolio of innovative bispecific antibodies to treat incurable cancer, and Ellipses Pharma Limited a global drug development company focused on accelerating the development of new oncology treatments, announce that they have entered into an exclusive licensing agreement for SRB22, a fully human bifunctional HER3:TRAIL fusion protein, which going forward will be known as EP0017. Under the agreement, Ellipses ...

Read More
news image

Pharma Tech

SCINEURO PHARMACEUTICALS AND MABYLON AG TO COLLABORATE ON DEVELOPMENT OF NOVEL THERAPEUTICS FOR NEUROLOGICAL DISEASES

SciNeuro Pharmaceuticals | October 26, 2021

SciNeuro Pharmaceuticals a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, and Mabylon AG, a leader in the discovery and characterization of human-derived antibodies against therapeutic targets, today announced the establishment of a multi-program collaboration and license agreement. Under the collaboration, MabSciNeuro and Mabylon will collaborate on multiple targets that encompass serious neurological diseases including TAR DNA bin...

Read More
news image

LANTERN PHARMA’S PROPRIETARY A.I. PLATFORM SURPASSES 450 MILLION DATA POINTS ACCELERATING ONCOLOGY DRUG DEVELOPMENT AND DRUG RESPONSE PREDICTION

Lantern Pharma | June 30, 2020

Lantern Pharma, a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and...

Read More
news image

Pharmacy Market

PAN-TB COLLABORATION ANNOUNCES THE START OF A PHASE 2 CLINICAL TRIAL TO EVALUATE TWO NOVEL TUBERCULOSIS TREATMENT REGIMENS

PRNewswire | August 10, 2023

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the Bill & Melinda Gates Medical Research Institute (Gates MRI). The trial will evaluate whether novel regimens that combine registered products and new chemical entities have the potential to effectively treat drug-sensitive TB (DS-TB) and inform the development of a "pan-TB" regimen capable of treating all forms of active pu...

Read More
news image

Business Insights

ELLIPSES PHARMA AND SUNROCK BIOPHARMA ENTER INTO A LICENSING AGREEMENT FOR A FIRST-IN-CLASS BIFUNCTIONAL HER3:TRAIL FUSION PROTEIN

SunRock Biopharma S.L | May 26, 2022

SunRock Biopharma S.L. a biopharmaceutical company that is developing a portfolio of innovative bispecific antibodies to treat incurable cancer, and Ellipses Pharma Limited a global drug development company focused on accelerating the development of new oncology treatments, announce that they have entered into an exclusive licensing agreement for SRB22, a fully human bifunctional HER3:TRAIL fusion protein, which going forward will be known as EP0017. Under the agreement, Ellipses ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us